As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.

Stephanie is the Vice President of Public Policy & Government Affairs (PPGA) for Biogen. Stephanie has had a distinguished career in health policy, government and the pharmaceutical and biotechnology industry that spans for more than 15 years. As the Vice President, U.S. PPGA, Stephanie is responsible for leading a team of lobbyists, policy and strategic alliance professionals on federal and state legislative issues, legislatures, executive branch officials and government administrations. In her role, she works collaboratively with Biogen’s internal leadership to develop and implement policy, lobbying and advocacy strategies that are focused on patient access and aligned with business goals. Prior to joining Biogen, Stephanie worked as a Vice President at United HealthGroup. She previously served as Senior Director of Public Policy and Reimbursement at Genentech, Vice President of Government Affairs at DaVita (now Healthcare Partners) and Vice President, Government Affairs at Achaogen. Stephanie has also served in multiple senior-leadership positions at the Centers for Medicare & Medicaid Services (CMS) as the Deputy Office Director. Stephanie is a registered nurse by background and received a graduate degree in Political Management and Policy from The George Washington University. She has been married to Charlie Dyson, the love of her life, for over 25 years.

Chris Leibman is the Head of Value, Access, Public Policy and Government Affairs at Biogen, where he leads the global value demonstration, patient access and pricing strategy development and execution across the Biogen portfolio, in addition to the US based Public Policy and Government Affairs organization. Prior to this role Chris lived in Zug, Switzerland where he led market Access and pricing at Biogen for Europe and Canada. Mr. Leibman joined Biogen in 2014 from Janssen Pharmaceuticals (J&J), where he served as head of Market Access and Policy: Neuroscience and led the team responsible for the development and execution of market access strategies and value evidence generation across the Neuroscience franchise. Prior to this, first with Élan Pharmaceuticals and then with Janssen AI following their program acquisition, Chris led the market access launch readiness activities across the Alzheimer Immunotherapy Program in partnership with Pfizer. Mr. Leibman has published and presented extensively on the benefits and costs of prescription drugs in Alzheimer’s disease, value frameworks in healthcare, and sustainable pricing in drug development. He brings two decades of diverse experiences in biopharmaceutical development, value demonstration, access, and working across multi-company alliances. Mr. Leibman holds a B.S. degree in Biology, from the University of Illinois at Urbana-Champaign and Doctor of Pharmacy from the University of Illinois at Chicago. Following his pharmacy degree, he completed a post-doc fellowship in health economics with GlaxoWellcome and earned a M.S. degree with focus in Pharmacoeconomics and Health Policy from the Ohio State University. Outside of work, Chris enjoys competitive bike racing and spending time with his wife and three kids.